CareDx free cash flow CDNA
Cash from operations less capital spending, by quarter and over the last twelve months, from 2013.
- Last 12 months, to Sep 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q3 FY26
- $11.1M
- −69% on a year earlier
- Fiscal year 2018
- −$6M
CareDx's twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q3 FY26, it was $11.1M, down 69% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2018 | −$6M | n/a |
| FY2017 | −$14.5M | n/a |
| FY2016 | −$17.1M | n/a |
| FY2015 | −$11M | n/a |
| FY2014 | −$4.1M | n/a |
| FY2013 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier |
|---|---|---|---|
| Q3 FY26 | $11.1M | −69% | |
| Q2 FY26 | $28.7M | +223% | |
| Q1 FY26 | $514K | n/a | |
| Q3 FY25 | $36.1M | n/a | |
| Q2 FY25 | $8.9M | n/a | |
| Q1 FY25 | −$28.2M | n/a | |
| Q3 FY21 | −$3.2M | −264% | |
| Q2 FY21 | $7M | −69% | |
| Q1 FY21 | −$34.9M | n/a | |
| Q3 FY20 | $2M | +906% | |
| Q2 FY20 | $22.4M | +529% | |
| Q1 FY20 | −$4.8M | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest CareDx's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| CDNACareDx | n/m |
| VCYTVeracyte | 4.2% |
| BLLNBillionToOne | 0.6% |
| LNTHLantheus | 5.9% |
| CAICaris Life Sciences | 1.4% |
| BIOBio-Rad Laboratories | 3.6% |
| RVTYRevvity | 3.3% |
| MEDPMedpace | 3.9% |
| DGXQuest Diagnostics | 5.0% |
| LHLabcorp | 4.0% |
| MTDMettler-Toledo International | 2.5% |
| Peer median | 3.8% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on CareDx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.